Li Jin, Liu Wei, Xu Yong Jun, Fu Qiang, Liu Ju
Department of Otolaryngology, Ordos Central Hospital, No. 23, Yijin Huoluo West Street, Dongsheng District, Ordos, Inner Mongolia, China.
Department of Otolaryngology, Ordos Mongolian Hospital, Ordos, Inner Mongolia, China.
Eur Arch Otorhinolaryngol. 2025 Feb;282(2):843-850. doi: 10.1007/s00405-024-09088-9. Epub 2024 Nov 29.
This study aimed to investigate the efficacy and safety of coseasonal initiation of Artemisia annua sublingual immunotherapy (SLIT) for children and adult patients with allergic rhinoconjunctivitis (ARC).
A total of 50 patients (aged 4-60 years) with ARC who visited hospital from July to September 2022 were enrolled and randomly divided into the SLIT (n = 25) and control group (n = 25). Patients in SLIT group received Artemisia annua SLIT and patients in control group only received symptomatic medication. The study continued for 1 year. Four nasal symptom scores, two eye symptom scores, and medication usage of the patients during 2021 (baseline) and 2023 pollen seasons were recorded, as well as adverse events (AEs) during the study.
Finally, 20 patients of SLIT group and 22 patients of control group completed this study. Compared with the baseline, the levels of total rhinoconjunctivitis symptom score (TRSS), total medication score (TMS), and combined symptom and medication score for rhinoconjunctivitis (CSMS-RC) experienced significant reductions after 1 year SLIT. Additionally, these outcomes also decreased significantly in SLIT group when compared with the control group during 2023 pollen season. Especially, there were more patients showed symptoms reduction, medication use decrease, and efficacy improvement in the SLIT group. Notably, no severe AEs were observed throughout the treatment course among patients receiving SLIT.
Coseasonal initiating Artemisia annua SLIT demonstrated clinical efficacy and safety for children and adult patients with ARC.
本研究旨在探讨在花粉季节同时开始使用青蒿舌下免疫疗法（SLIT）治疗儿童和成人变应性鼻结膜炎（ARC）的疗效和安全性。
纳入2022年7月至9月到医院就诊的50例ARC患者（年龄4 - 60岁），随机分为SLIT组（n = 25）和对照组（n = 25）。SLIT组患者接受青蒿SLIT治疗，对照组患者仅接受对症药物治疗。研究持续1年。记录患者在2021年（基线）和2023年花粉季节的四项鼻部症状评分、两项眼部症状评分以及药物使用情况，以及研究期间的不良事件（AE）。
最终，SLIT组20例患者和对照组22例患者完成了本研究。与基线相比，SLIT治疗1年后，变应性鼻结膜炎总症状评分（TRSS）、总药物评分（TMS）以及变应性鼻结膜炎症状与药物综合评分（CSMS - RC）均显著降低。此外，在2023年花粉季节，SLIT组的这些指标与对照组相比也显著降低。特别是，SLIT组有更多患者症状减轻、药物使用减少且疗效改善。值得注意的是，接受SLIT治疗的患者在整个治疗过程中未观察到严重不良事件。
在花粉季节同时开始使用青蒿SLIT对儿童和成人ARC患者显示出临床疗效和安全性。
